AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
Tolero Pharmaceuticals and AbbVie collaborate to advance AML treatment
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their respective drugs, alvocidib and venetoclax, for the ... Read More